TY - JOUR
T1 - Patterns of symptom development in patients with motor neuron disease
AU - Walhout, Renée
AU - Verstraete, Esther
AU - Van Den Heuvel, Martijn P
AU - Veldink, Jan H
AU - Van Den Berg, Leonard H
N1 - Funding Information:
R. Walhout reports no disclosures. E. Verstraete received a consultancy fee from Biogen Idec. MPvdH received a grant from The Netherlands Organization for Health Research and Development (Veni scheme), from the ALS Foundation Netherlands and from MQ. J.H. Veldink reports no disclosures. LHvdB received a grant from The Netherlands Organization for Health Research and Development (Vici scheme), travel grants and consultancy fees from Baxalta; serves on scientific advisory boards for Prinses Beatrix Spierfonds, Thierry Latran Foundation, Cytokinetics and Biogen.
Funding Information:
This study was supported by the ALS Foundation Netherlands, Prinses Beatrix Spierfonds, the European Community’s Health Seventh Framework Programme (grant agreement n° 259867), and the SOPHIA project (funded through the EU Joint Programme – Neurodegenerative Disease Research, JPND).
Publisher Copyright:
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/2
Y1 - 2018/2
N2 - Objective: To investigate whether symptom development in motor neuron disease (MND) is a random or organized process. Methods: Six hundred patients with amyotrophic lateral sclerosis (ALS), upper motor neuron (UMN) or lower motor neuron (LMN) phenotypes were invited for a questionnaire concerning symptom development. A binomial test was used to examine distribution of symptoms from site of onset. Development of symptoms over time was evaluated by Kaplan-Meier analysis. Results: There were 470 respondents (ALS = 254; LMN = 100; UMN = 116). Subsequent symptoms were more often in the contralateral limb following unilateral limb onset (ALS: arms p = 1.05 × 10
−8 , legs p < 2.86 × 10
−15 ; LMN phenotype: arms p = 6.74 × 10
−9 , legs p = 6.26 × 10
−6 ; UMN phenotype: legs p = 4.07 × 10
−14 ). In patients with limb onset, symptoms occurred significantly faster in the contralateral limb, followed by the other limbs and lastly by the bulbar region. Patterns of non-contiguous symptom development were also reported: leg symptoms followed bulbar onset in 30%, and bulbar symptoms followed leg onset in 11% of ALS patients. Conclusions: Preferred spread of symptoms from one limb to the contralateral limb, and to adjacent sites appears to be a characteristic of MND phenotypes, suggesting that symptom spread is organized, possibly involving axonal connectivity. Non-contiguous symptom development, however, is not uncommon, and may involve other factors.
AB - Objective: To investigate whether symptom development in motor neuron disease (MND) is a random or organized process. Methods: Six hundred patients with amyotrophic lateral sclerosis (ALS), upper motor neuron (UMN) or lower motor neuron (LMN) phenotypes were invited for a questionnaire concerning symptom development. A binomial test was used to examine distribution of symptoms from site of onset. Development of symptoms over time was evaluated by Kaplan-Meier analysis. Results: There were 470 respondents (ALS = 254; LMN = 100; UMN = 116). Subsequent symptoms were more often in the contralateral limb following unilateral limb onset (ALS: arms p = 1.05 × 10
−8 , legs p < 2.86 × 10
−15 ; LMN phenotype: arms p = 6.74 × 10
−9 , legs p = 6.26 × 10
−6 ; UMN phenotype: legs p = 4.07 × 10
−14 ). In patients with limb onset, symptoms occurred significantly faster in the contralateral limb, followed by the other limbs and lastly by the bulbar region. Patterns of non-contiguous symptom development were also reported: leg symptoms followed bulbar onset in 30%, and bulbar symptoms followed leg onset in 11% of ALS patients. Conclusions: Preferred spread of symptoms from one limb to the contralateral limb, and to adjacent sites appears to be a characteristic of MND phenotypes, suggesting that symptom spread is organized, possibly involving axonal connectivity. Non-contiguous symptom development, however, is not uncommon, and may involve other factors.
KW - upper motor neuron
KW - lower motor neuron
KW - symptom development
KW - Motor neuron disease
KW - amyotrophic lateral sclerosis
KW - Humans
KW - Middle Aged
KW - Kaplan-Meier Estimate
KW - Male
KW - Disease Progression
KW - Young Adult
KW - Phenotype
KW - Aged, 80 and over
KW - Motor Neurons/physiology
KW - Adult
KW - Female
KW - Surveys and Questionnaires
KW - Aged
KW - Amyotrophic Lateral Sclerosis/diagnosis
UR - https://www.scopus.com/pages/publications/85031662921
U2 - 10.1080/21678421.2017.1386688
DO - 10.1080/21678421.2017.1386688
M3 - Article
C2 - 29037065
SN - 2167-8421
VL - 19
SP - 21
EP - 28
JO - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
IS - 1-2
ER -